TNFSF10 and neoplasm: Viewed as the most favorable property of TRAIL as a drug candidate was the fact that it selectively induced apoptosis in transformed tumor cells but not in normal cells in vivo, without causing toxicity following systemic applications [5–7], one of the key discoveries among members of the TNF superfamily [8, 9].